DUBLIN, Oct. 13, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Nonalcoholic Steatohepatitis (NASH) Market (Pipeline analysis, drug class, clinical trials and Geography) - Research Report, 2013 - 2020" report to their offering.
Nonalcoholic Steatohepatitis (NASH) also known as silent disease is a type of fatty liver disease, which mainly affects people with diabetes and obesity. Symptoms of NASH are found among all demographics (from children to adults); however, they are more prevalent in younger people. Corner stage of cirrhosis is a form of NASH that can be reversed with proper medication. Moreover, most of the NASH specific pharmaceutical solution are in clinical trial phase .
Additionally, the absence of efficient diagnostic technologies acts as a major hurdle for the research of NASH therapeutics. Nevertheless, the emergence of novel biomarker technologies and improvements in liver biopsy technologies are expected to bring about an evolution in the diagnosis of NASH and other fatty liver diseases. Global non-alcoholic Steatohepatitis market is expected to garner $1693.2 million by 2020 growing at a CAGR of 25.6% during 2014-2020.
Increase in cycles of clinical trials and their success rate has increased the probability of industries receiving commercial approval for NASH therapeutics by the end of 2017. The market growth is restricted by factors such as NASH's complex and enigmatic physiological structure and inefficient diagnostics technology; these factors could also prolong the commercialization process for NASH therapeutics. Nevertheless, certain key players competing in the market are conducting extensive research on NASH therapeutics and are receiving positive results from clinical trials.
The results of a recent clinical trial conducted by Genfit satisfied concerns of the EMA (European Medicines Agency), regarding the efficacy and safety of GFT5o5 as therapeutics for NASH. The EMA finally recommended that the development of GFT5o5 as a therapeutic drug progress to Phase III of the clinical trial. Additionally, Dainippon Sumitomo Pharma (DSP), a partner of Intercept Pharmaceuticals, initiated a phase 2 clinical trial to test the safety and efficacy of one daily dose of OCA in 200 adult NASH patients. The trial is expected to be completed in the first half of 2016.
Geographically, the NASH therapeutics market is segmented into North America, Europe, Asia-Pacific and LAMEA. Geographical analysis of NASH therapeutics is conducted with reference to research and commercialization. North America, which has the highest number of research initiatives concerning NASH, holds nearly half of the global market share. It is also one of the regions with the most cases of NASH and other non-alcoholic fatty liver diseases.
European countries are equally contributing to the growth of the NASH therapeutics market in terms of research and commercialization; however, failure to comply with regulations and decreased number of research initiatives causes them to be relegated to the second place in this market.
Key Topics Covered:
CHAPTER 1 INTRODUCTION
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET BEYOND: WHAT TO EXPECT BY 2025
CHAPTER 4 MARKET OVERVIEW
CHAPTER 5 GLOBAL NONALCOHOLIC STEATOHEPATITIS MARKET BY DRUG TYPES
CHAPTER 6 GLOBAL NONALCOHOLIC STEATOHEPATITIS MARKET (PIPELINE DRUG ANALYSIS)BY GEOGRAPHY, 2013-20206
CHAPTER 7 COMPANY PROFILES
- Enzo Biochem
- Gilead Science
- Intercepts Pharmaceuticals
- Novo Nordisk
- Raptor Pharmaceutical Corp.
For more information visit http://www.researchandmarkets.com/research/s3gvzp/global
Media Contact: Laura Wood, +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets